期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Experimental Study of the Effect of the Bax Gene on Human Hepatocellular Carcinoma and Therapy via Hepatic Artery Delivery
1
作者 Zhi Guo Wenge Xing +5 位作者 Haishan Yang Lin Wang Yunpeng Jiang Bingyu Huang Gong Nu Yan Lu 《Chinese Journal of Clinical Oncology》 CSCD 2005年第4期731-736,共6页
OBJECTIVE To investigate apoptosis induced by Bax in hepatocellular carcinoma cells and to examine the results of 2 different routes for in vivo gene delivery. METHODS The anti-hepatocellular carcinoma activity of the... OBJECTIVE To investigate apoptosis induced by Bax in hepatocellular carcinoma cells and to examine the results of 2 different routes for in vivo gene delivery. METHODS The anti-hepatocellular carcinoma activity of the Bax gene transferred to the human hepatocellular carcinoma QGY7703 cell line was examined. In addition the Bax gene was transferred in vivo in mice via the caudal vein or hepatic artery to investigate the differences in target organ and non-target organ transfection. RESULTS 1)The Bax gene mediated by a binary adenoviral vector system induced apoptosis in the human hepatic carcinoma QFY7703 cell line. The cell apoptotic rate in the experimental group (Bax) was 50.2±6.9% but only 32.1 ± 9.7% in the Ad/CMV-p53 group, showing that the Bax-apoptotic rate was significantly higher than the control group. 2) LacZ expression was higher in the target organ (liver) when given through the hepatic artery than through the tail vein. In contrast, LacZ expression in the nontarget organs was higher if given through the tail vein compared to the hepatic artery. CONCLUSION Superselective hepatic artery delivery with Bax gene therapy is safe, specific, effective and has low toxicity. This study provided the basis for Bax-gene therapy via the hepatic artery in vivo. 展开更多
关键词 BAX hepatocellular carcinoma hepatic artery
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部